{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=26",
    "query": {
      "condition": "Multiple Diseases",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 12226,
    "total_pages": 1223,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T15:34:11.725Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00478296",
      "title": "Pulmonary Hypertension in Trisomy 21 Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Healthcare of Atlanta",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "8 Days",
        "sex": "ALL",
        "summary": "Up to 8 Days"
      },
      "enrollment_count": 1,
      "start_date": "2004-10",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-16",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00478296"
    },
    {
      "nct_id": "NCT04099888",
      "title": "PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Fimaporfin and Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PCI Biotech AS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-05-23",
      "completion_date": "2022-05-06",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099888"
    },
    {
      "nct_id": "NCT00078091",
      "title": "Genetics and Clinical Characteristics of Bardet-Biedl Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bardet-Biedl Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 194,
      "start_date": "2004-02-17",
      "completion_date": "2016-02-05",
      "has_results": false,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00078091"
    },
    {
      "nct_id": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma",
        "SCC - Squamous Cell Carcinoma",
        "Basal Cell Carcinoma",
        "BCC",
        "BCC - Basal Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Sebaceous Carcinoma",
        "Extramammary Paget Disease",
        "Kaposi Sarcoma",
        "Head and Neck Squamous Cell Carcinoma",
        "HNSCC",
        "Adnexal Carcinoma",
        "Angiosarcoma",
        "Cutaneous Neoplasm",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Refractory Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "MQ719",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2023-05-04",
      "completion_date": "2028-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05859074"
    },
    {
      "nct_id": "NCT00597818",
      "title": "Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSAID-induced Gastroduodenal Injury",
        "Ulcers",
        "Rheumatoid Arthritis",
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Cobiprostone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal anti-inflammatory drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sucampo Pharma Americas, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 121,
      "start_date": "2007-08",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597818"
    },
    {
      "nct_id": "NCT04838860",
      "title": "Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Multicentric Castleman's Disease"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RECORDATI GROUP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-03-31",
      "completion_date": "2021-04-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 1,
      "location_summary": "Lansing, Michigan",
      "locations": [
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04838860"
    },
    {
      "nct_id": "NCT01210560",
      "title": "Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autosomal Dominant Polycystic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Tolvaptan MR",
          "type": "DRUG"
        },
        {
          "name": "Tolvaptan IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01210560"
    },
    {
      "nct_id": "NCT01138735",
      "title": "Epiduo Pediatric Acne Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne"
      ],
      "interventions": [
        {
          "name": "adapalene/benzoyl peroxide",
          "type": "DRUG"
        },
        {
          "name": "Topical Gel Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "9 Years to 11 Years"
      },
      "enrollment_count": 285,
      "start_date": "2010-06",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • San Diego, California • Santa Rosa, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01138735"
    },
    {
      "nct_id": "NCT00041925",
      "title": "Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Vascular Diseases",
        "Arterial Occlusive Diseases",
        "Ischemia",
        "Graft Occlusion, Vascular",
        "Hyperplasia"
      ],
      "interventions": [
        {
          "name": "CGT003 (E2F Duplex Decoy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anesiva, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1400,
      "start_date": "2001-11",
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2005-07-15",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 116,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041925"
    },
    {
      "nct_id": "NCT00102518",
      "title": "Aripiprazole Open-Label, Safety and Tolerability Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 325,
      "start_date": "2004-09",
      "completion_date": "2007-02",
      "has_results": true,
      "last_update_posted_date": "2012-08-31",
      "last_synced_at": "2026-11-08T15:34:11.725Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00102518"
    }
  ]
}